Trial Profile
A Randomized, Multicenter, Single Blind Study in Men With Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms ProACT
- Sponsors Dendreon Corporation
- 23 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2014 According to a Dendreon Corporation media release, the results of this and two other trials (700007675 and 700195649) will be presented at the 2014 American Urological Association Annual Meeting.
- 06 May 2013 Results presented at the 108th Annual Meeting of the American Urological Association.